Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMO: Tilsotolimod, Ipilimumab, and Nivolumab in Advanced Cancers
NCT04270864Phase 1Terminated
- Sponsor
- Gustave Roussy
- Start
- Apr 2020
- Primary completion
- Jul 2021
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of tilsotolimod in cancer, non-small cell lung cancer (NSCLC), melanoma and 1 more, sponsored by Gustave Roussy. Started Apr 2020; status: terminated.
02
Drugs
tilsotolimod
03
Conditions
cancernon-small cell lung cancer (NSCLC)melanomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04270864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270864.